论文部分内容阅读
对104例非霍奇金淋巴瘤(NHL)患者应用COPBLAM方案并用粒细胞集落刺激因子(G-CSF),研讨其疗效及副作用。对象为未治中度或高度恶性NHL,中敬年龄54岁(18～83岁),其中Ⅱ期22例,Ⅲ期52例,Ⅳ期30例。病理组织学为弥漫性大细胞型75例,弥漫性中细胞型18例及弥漫性混合细胞型11例。COPBLAM方案以Laurence法为准,环磷酰胺(CPM)500mg/m~2。(原法400mg/m~2),静滴,第1天;长春新碱1mg/m~2,静注,第1天;阿霉素(ADR)50mg/m~2(原法40mg/m~2),静滴,第1天;泼尼松龙40mg/m~2,口服,第1～10天;甲基芐肼100mg/m~2,口服,第1～10天;
A total of 104 patients with non-Hodgkin’s lymphoma (NHL) were treated with COBLAM and granulocyte colony-stimulating factor (G-CSF) was used to study the efficacy and side effects. The subjects were untreated or highly malignant NHL. Zhongjing was 54 years old (18-83 years old), of whom 22 were in stage II, 52 in stage III, and 30 in stage IV. Histopathology included 75 cases of diffuse large cell type, 18 cases of diffuse middle cell type, and 11 cases of diffuse mixed cell type. The COPBLAM protocol is based on the Laurence method with cyclophosphamide (CPM) 500mg/m~2. (original method 400 mg/m~2), intravenous infusion, first day; vincristine 1 mg/m~2, intravenous injection, first day; adriamycin (ADR) 50 mg/m~2 (original method 40 mg/m ~2), intravenous drip, on the first day; prednisolone 40mg/m~2, orally, on the 1st to 10th days; methylbenzamidine 100mg/m~2, orally, on the 1st to 10th days;